Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania. Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to urologists, endocrinologists, orthopedists and select primary care physicians. The Company’s product, Testim, is a topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism. Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as low energy, loss of libido, adverse changes in body composition, irritability and poor concentration. The product pipeline of the Company includes XIAFLEX (clostridial collagenase for injection) for the treatment of Dupuytren’s contracture (Dupuytren’s), XIAFLEX for the treatment of Peyronie’s disease (Peyronie’s), XIAFLEX for the treatment of Adhesive Capsulitis (frozen shoulder syndrome), AA4010, treatment for overactive bladder using the transmucosal film delivery system and fentanyl pain product using the transmucosal film delivery system.

Quantum was founded in 1981. Quantum, Inc. company distributes dozens of natural products to consumers and health food retailers in the US and Canada. Quantum's inventory includes vitamins, insect repellents, and skin care products. The firm also manufactures items designed for women's and men's health, age management, weight loss, and immune system health. In all, Quantum offers about 60 different products sold individually as well as in "value packs" of related products such as its outdoor kit which offers insect repellant, sun block, insect bite treatment, and anti-itch cream. The company also sells anti-aging, cold sore, and immune support kits.

Servier is an independent, French pharmaceutical company which manufactures and sells drugs to combat cardiovascular diseases, such as coronary artery disease, hypertension, and stroke. Cardiovascular drugs account for about two-thirds of the company's annual revenues. It also produces medicines to treat diabetes, venous disease, and cancer. Annually, more than 700 million boxes of drugs are produced by Servier. Its pharmaceutics can be found in 140 countries; 80% of its sales are generated internationally.

WuXi PharmaTech (Cayman) Inc. (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the R&D process to its customers, which include pharmaceutical, biotechnology and medical device companies. The Company operates in two segments: laboratory services and manufacturing. Laboratory services for pharmaceutical, biotechnology and medical device companies. Manufacturing segment services for producing advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials. In January 2008, the Company completed its acquisition of AppTec Laboratory Services, Inc.

Osiris Therapeutics, Inc. company was founded in 1992 and is headquartered in Columbia, Maryland. Osiris Therapeutics, Inc., a stem cell therapeutic company, develops products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States. The company's principal product includes Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, Crohn's disease, and acute radiation syndrome; and in phase II clinical trials for the treatment of Type I diabetes mellitus, acute myocardial infarction, and chronic obstructive pulmonary disease. Its product also consists of Chondrogen, a Phase II clinical trial product for the treatment of osteoarthritis and the reduction of pain in the knee. Osiris Therapeutics has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for distributing Prochymal for the treatment of GvHD in Japan.

StemCells, Inc. company was founded in 1988 and is based in Palo Alto, California. StemCells, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. In April 2009, StemCells, Inc. completed the acquisition of substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.

Medivation, Inc. was founded in 2003 and is based in San Francisco, California. Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and castration-resistant prostate cancer. Its product pipeline includes Dimebon, which is in pivotal Phase 3 trial in patients with mild-to-moderate Alzheimer's disease, and is in Phase 2 clinical trial in patients with mild-to-moderate Huntington's disease; and MDV3100, a Phase 1-2 clinical trial product in patients with castration-resistant prostate cancer. The company has a collaboration agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases, as well as an agreement to develop and commercialize MDV3100, an investigational drug for the treatment of prostate cancer.

Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction and obsessive-compulsive disorders. Its products include CPP-109, a chemical compound gamma-vinyl-GABA/vigabatrin, a Phase II clinical trial product for the treatment of cocaine addiction. The company also conducts a Phase II clinical trial of CPP-109 to evaluate its use in the treatment of methamphetamine addiction. In addition, it has a license agreement with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions.

VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.

Founded in 1929, the not-for-profit organization is a leading researcher of human diseases, their causes, and their potential cures. Much of its research into mammalian genetics is focused on mice, which share a similar genetic makeup to humans. In addition to its own research in areas such as cancer, immunology, and metabolic disease, the organization maintains colonies of mice and supplies them under the brand name JAX to other laboratories around the globe. Additionally, The Jackson Laboratory offers educational programs -- including internships, workshops, and predoctoral programs -- for both current and future scientists.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.